Literature DB >> 28729445

Preferential Disruption of Prefrontal GABAergic Function by Nanomolar Concentrations of the α7nACh Negative Modulator Kynurenic Acid.

Eden Flores-Barrera1, Daniel R Thomases1, Daryn K Cass1, Ajay Bhandari1, Robert Schwarcz2, John P Bruno3, Kuei Y Tseng4.   

Abstract

Increased concentrations of kynurenic acid (KYNA) in the prefrontal cortex (PFC) are thought to contribute to the development of cognitive deficits observed in schizophrenia. Although this view is consistent with preclinical studies showing a negative impact of prefrontal KYNA elevation on executive function, the mechanism underlying such a disruption remains unclear. Here, we measured changes in local field potential (LFP) responses to ventral hippocampal stimulation in vivo and conducted whole-cell patch-clamp recordings in brain slices to reveal how nanomolar concentrations of KYNA alter synaptic transmission in the PFC of male adult rats. Our data show that prefrontal infusions of KYNA attenuated the inhibitory component of PFC LFP responses, a disruption that resulted from local blockade of α7-nicotinic acetylcholine receptors (α7nAChR). At the cellular level, we found that the inhibitory action exerted by KYNA in the PFC occurred primarily at local GABAergic synapses through an α7nAChR-dependent presynaptic mechanism. As a result, the excitatory-inhibitory ratio of synaptic transmission becomes imbalanced in a manner that correlates highly with the level of GABAergic suppression by KYNA. Finally, prefrontal infusion of a GABAAR positive allosteric modulator was sufficient to overcome the disrupting effect of KYNA and normalized the pattern of LFP inhibition in the PFC. Thus, the preferential inhibitory effect of KYNA on prefrontal GABAergic transmission could contribute to the onset of cognitive deficits observed in schizophrenia because proper GABAergic control of PFC output is one key mechanism for supporting such cortical functions.SIGNIFICANCE STATEMENT Brain kynurenic acid (KYNA) is an astrocyte-derived metabolite and its abnormal elevation in the prefrontal cortex (PFC) is thought to impair cognitive functions in individuals with schizophrenia. However, the mechanism underlying the disrupting effect of KYNA remains unclear. Here we found that KYNA biases the excitatory-inhibitory balance of prefrontal synaptic activity toward a state of disinhibition. Such disruption emerges as a result of a preferential suppression of local GABAergic transmission by KYNA via presynaptic inhibition of α7-nicotinic acetylcholine receptor signaling. Therefore, the degree of GABAergic dysregulation in the PFC could be a clinically relevant contributing factor for the onset of cognitive deficits resulting from abnormal increases of cortical KYNA.
Copyright © 2017 the authors 0270-6474/17/377921-09$15.00/0.

Entities:  

Keywords:  GABA; kynurenic acid; local field potentials; nicotinic receptor; prefrontal cortex; ventral hippocampus

Mesh:

Substances:

Year:  2017        PMID: 28729445      PMCID: PMC5559765          DOI: 10.1523/JNEUROSCI.0932-17.2017

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  44 in total

1.  Modified neocortical and cerebellar protein expression and morphology in adult rats following prenatal inhibition of the kynurenine pathway.

Authors:  Mazura Pisar; Caroline M Forrest; Omari S Khalil; Kara McNair; Maria C J Vincenten; Susana Qasem; L Gail Darlington; Trevor W Stone
Journal:  Brain Res       Date:  2014-06-21       Impact factor: 3.252

2.  Downregulated kynurenine 3-monooxygenase gene expression and enzyme activity in schizophrenia and genetic association with schizophrenia endophenotypes.

Authors:  Ikwunga Wonodi; O Colin Stine; Korrapati V Sathyasaikumar; Rosalinda C Roberts; Braxton D Mitchell; L Elliot Hong; Yasushi Kajii; Gunvant K Thaker; Robert Schwarcz
Journal:  Arch Gen Psychiatry       Date:  2011-07

3.  Exposure to kynurenic acid during adolescence produces memory deficits in adulthood.

Authors:  Cynthia O Akagbosu; Gretchen C Evans; Danielle Gulick; Raymond F Suckow; David J Bucci
Journal:  Schizophr Bull       Date:  2010-12-20       Impact factor: 9.306

Review 4.  GABAergic Function as a Limiting Factor for Prefrontal Maturation during Adolescence.

Authors:  Adriana Caballero; Kuei Y Tseng
Journal:  Trends Neurosci       Date:  2016-05-24       Impact factor: 13.837

5.  The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications.

Authors:  C Hilmas; E F Pereira; M Alkondon; A Rassoulpour; R Schwarcz; E X Albuquerque
Journal:  J Neurosci       Date:  2001-10-01       Impact factor: 6.167

6.  A glycine site associated with N-methyl-D-aspartic acid receptors: characterization and identification of a new class of antagonists.

Authors:  M Kessler; T Terramani; G Lynch; M Baudry
Journal:  J Neurochem       Date:  1989-04       Impact factor: 5.372

7.  Increased cortical kynurenate content in schizophrenia.

Authors:  R Schwarcz; A Rassoulpour; H Q Wu; D Medoff; C A Tamminga; R C Roberts
Journal:  Biol Psychiatry       Date:  2001-10-01       Impact factor: 13.382

Review 8.  The neonatal ventral hippocampal lesion as a heuristic neurodevelopmental model of schizophrenia.

Authors:  Kuei Y Tseng; R Andrew Chambers; Barbara K Lipska
Journal:  Behav Brain Res       Date:  2008-12-03       Impact factor: 3.332

9.  Early developmental elevations of brain kynurenic acid impair cognitive flexibility in adults: reversal with galantamine.

Authors:  K S Alexander; A Pocivavsek; H-Q Wu; M L Pershing; R Schwarcz; J P Bruno
Journal:  Neuroscience       Date:  2013-02-06       Impact factor: 3.590

10.  Chronic Antipsychotic Treatment in the Rat - Effects on Brain Interleukin-8 and Kynurenic Acid.

Authors:  Markus K Larsson; Lilly Schwieler; Michel Goiny; Sophie Erhardt; Göran Engberg
Journal:  Int J Tryptophan Res       Date:  2015-09-20
View more
  13 in total

1.  EGF Treatment Improves Motor Behavior and Cortical GABAergic Function in the R6/2 Mouse Model of Huntington's Disease.

Authors:  Felecia M Marottoli; Mercedes Priego; Eden Flores-Barrera; Rohan Pisharody; Steve Zaldua; Kelly D Fan; Giri K Ekkurthi; Scott T Brady; Gerardo A Morfini; Kuei Y Tseng; Leon M Tai
Journal:  Mol Neurobiol       Date:  2019-05-19       Impact factor: 5.590

2.  Activation of alpha7 nicotinic and NMDA receptors is necessary for performance in a working memory task.

Authors:  David Phenis; Sarah A Vunck; Valentina Valentini; Hugo Arias; Robert Schwarcz; John P Bruno
Journal:  Psychopharmacology (Berl)       Date:  2020-03-11       Impact factor: 4.530

3.  Prenatal THC exposure raises kynurenic acid levels in the prefrontal cortex of adult rats.

Authors:  Sarah Beggiato; Alessandro Ieraci; Maria Cristina Tomasini; Robert Schwarcz; Luca Ferraro
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2020-02-04       Impact factor: 5.067

4.  Downregulation of parvalbumin expression in the prefrontal cortex during adolescence causes enduring prefrontal disinhibition in adulthood.

Authors:  Adriana Caballero; Eden Flores-Barrera; Daniel R Thomases; Kuei Y Tseng
Journal:  Neuropsychopharmacology       Date:  2020-05-13       Impact factor: 7.853

5.  MK-801 Exposure during Adolescence Elicits Enduring Disruption of Prefrontal E-I Balance and Its Control of Fear Extinction Behavior.

Authors:  Eden Flores-Barrera; Daniel R Thomases; Kuei Y Tseng
Journal:  J Neurosci       Date:  2020-05-19       Impact factor: 6.167

6.  Importance of kynurenine 3-monooxygenase for spontaneous firing and pharmacological responses of midbrain dopamine neurons: Relevance for schizophrenia.

Authors:  Maximilian Tufvesson-Alm; Lilly Schwieler; Robert Schwarcz; Michel Goiny; Sophie Erhardt; Göran Engberg
Journal:  Neuropharmacology       Date:  2018-06-05       Impact factor: 5.250

7.  Prefrontal α7nAChR Signaling Differentially Modulates Afferent Drive and Trace Fear Conditioning Behavior in Adolescent and Adult Rats.

Authors:  Anabel M M Miguelez Fernández; Hanna M Molla; Daniel R Thomases; Kuei Y Tseng
Journal:  J Neurosci       Date:  2021-01-21       Impact factor: 6.167

Review 8.  The origin of NMDA receptor hypofunction in schizophrenia.

Authors:  Kazu Nakazawa; Kiran Sapkota
Journal:  Pharmacol Ther       Date:  2019-10-16       Impact factor: 12.310

9.  Galantamine-Memantine Combination as an Antioxidant Treatment for Schizophrenia.

Authors:  Maju Mathew Koola; Samir Kumar Praharaj; Anilkumar Pillai
Journal:  Curr Behav Neurosci Rep       Date:  2019-05-17

10.  Effects of neuroactive metabolites of the tryptophan pathway on working memory and cortical thickness in schizophrenia.

Authors:  Junchao Huang; Jinghui Tong; Ping Zhang; Yanfang Zhou; Yimin Cui; Shuping Tan; Zhiren Wang; Fude Yang; Peter Kochunov; Joshua Chiappelli; Baopeng Tian; Li Tian; Yunlong Tan; L Elliot Hong
Journal:  Transl Psychiatry       Date:  2021-04-01       Impact factor: 6.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.